Topics:
Thoracic Malignancies • Medical Oncology
How will you decide between neoadjuvant CheckMate 816 approach vs adjuvant IMpower010 approach in a fit patient with EGFR negative resectable Stage II-III NSCLC patient with PD-L1 high expression tumor?
Do you use specific PDL-1 assays for each approach?
Answer from: Medical Oncologist at Academic Institution
In general, our multi-d group believes in neoadj approach to shrink the tumor and apply systemic therapy at the earliest time point. Most neoadj approaches also continue the I/O after surgery if there is a good response. It may be that patients with a complete path response or without ctDNA may not ...
Sign in or Register to read more